Skip to main content
TipRanks
Go Ultimate75% OFF

Poxel SA (POXEL) AI Stock Analysis

8 Followers
FR:POXEL

Poxel SA

(Paris:POXEL)

Select Model
Rating:46Neutral
Price Target:EUR 0.37â–²(172.26% Upside)
Action:reiterated
Date:02/03/26

Poxel's score is heavily weighed down by its critical financial condition, including negative equity and high debt, which pose a going-concern risk. While technical indicators show some short-term strength, the overbought RSI and lack of earnings limit upside. The negative P/E further underscores the company's unprofitability. Overall, the stock carries very high risk.

Positive Factors
Commercial partnership with Sumitomo PharmaA revenue-generating, arm’s-length commercialization partnership in Japan provides durable non-dilutive cash via milestones/royalties and shifts commercialization burden to an established local partner. This reduces short-term capex needs and supports predictable collaboration receipts over coming quarters.
Negative Factors
Highly stressed balance sheetDeep negative equity combined with rising debt materially limits financial flexibility, increasing refinancing and dilution risk. Over a multi‑month horizon this constrains runway for R&D and commercialization investments and raises the probability management must seek costly external funding.

Poxel SA (POXEL) vs. iShares MSCI France ETF (EWQ)

-50%-25%0%25%50%75%100%FR:POXEL-39.11%EWQ-0.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 11.01M
Dividend Yield
―
Average Volume (3M)
670.86K
Price to Earnings (P/E)
-0.4
Beta (1Y)
-0.08
Revenue Growth
―
EPS Growth
―
Country
France
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Poxel SA Business Overview & Revenue Model

Company Description

Poxel S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments. Its most advanced investigational drug, Imeglimin, is a...

How the Company Makes Money

Poxel makes money primarily through (1) product-related income from TWYMEEG (imeglimin) in Japan via its partnership with Sumitomo Pharma—this has historically included milestone payments and other collaboration-related receipts tied to development,...

Poxel SA Financial Statement Overview

Summary

Revenue growth and narrowing operating losses are positive, but negative equity, high debt, and negative operating cash flows indicate severe financial distress and going-concern risk. The overall financial position is precarious.

Income Statement

20Very Negative

Balance Sheet

5Very Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue7.66M6.64M1.98M674.00K13.40M6.81M
Gross Profit3.95M3.66M1,0002,00013.34M6.81M
EBITDA-3.07M-4.32M-12.17M-28.02M-22.52M-29.71M
Net Income-13.66M-18.30M-35.09M-31.40M-23.76M-31.86M
Balance Sheet
Total Assets5.00M14.93M4.82M34.71M54.89M65.08M
Cash, Cash Equivalents and Short-Term Investments2.06M3.66M2.34M13.06M32.29M40.20M
Total Debt60.99M69.71M47.03M43.44M35.14M23.62M
Total Liabilities66.41M73.87M53.90M52.95M46.68M38.20M
Stockholders Equity-61.40M-58.94M-49.10M-18.24M8.21M27.07M
Cash Flow
Free Cash Flow7.54M03.05M-21.84M-16.94M-26.03M
Operating Cash Flow-7.21M-17.61M-13.98M-21.81M-16.89M-25.75M
Investing Cash Flow28.00K92.00K41.00K-5,000-42.00K52.00K
Financing Cash Flow6.43M18.82M3.23M2.58M9.03M28.71M

Poxel SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:POXEL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:MEDCLFR:MEDCL61NeutralEUR 980.50M-29.96――-23.21%-50.69%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:IVAFR:IVA50NeutralEUR 756.76M-5.97-1625.48%―-99.64%68.67%
FR:POXELFR:POXEL46NeutralEUR 7.36M-0.3633.88%―――
FR:GNFTFR:GNFT45NeutralEUR 525.95M-5.17279.22%―27.70%-162.89%
FR:ALVALFR:ALVAL44NeutralEUR 20.61M-1.97-84.11%―183.47%57.15%
FR:ALGAEFR:ALGAE37UnderperformEUR 47.33M-4.54-32.62%―3.22%24.05%

* Healthcare Sector Average

Performance Comparison

0%100%200%FR:POXELFR:GNFTFR:IVAFR:ALVALFR:ALGAEFR:MEDCLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:POXEL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:POXELPoxel SA0.14-0.10-41.20%
FR:GNFTGenfit SA10.546.73176.79%
FR:IVAInventiva SA3.17-0.33-9.57%
FR:ALVALValbiotis SA0.58-0.12-16.79%
FR:ALGAEFermentalg SA0.40-0.05-11.83%
FR:MEDCLMedinCell SA27.26-0.86-3.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Feb 03, 2026